LENZ Therapeutics will announce its first quarter 2026 financial results and recent corporate highlights in a webcast on May 11, 2026. The company, known for commercializing VIZZ®, the first FDA-approved eye drop for presbyopia, is expanding its global reach with ongoing licensing partnerships. LENZ management will also participate in the Bank of America Global Healthcare Conference in mid-May to engage with investors. This update is important as it reflects LENZ's progress in commercializing a novel treatment for a widespread vision condition affecting millions worldwide.
Chery Group inaugurated the Rosslyn Plant in South Africa, marking a key step in its global expansion and local market integration. The plant, originally built in 1963, will retain 692 employees and create up to 3,000 supply chain jobs, with producti...
Prediction market data shows an 86% chance Nvidia will trade below $192 at some point in July 2026, with a 60% chance of reaching $208 but only a 32% chance of exceeding $216. Traders expect the stock to remain range-bound between $184 and $208, refl...
Michael Saylor, Strategy's executive chairman, argues that Bitcoin's next phase will focus less on protocol changes and more on its role in finance as a monetary network. He emphasizes Bitcoin as digital capital used for settlement, reserves, and col...
XRP has moved into a medium-term bullish zone after breaking above the middle Bollinger Band line, ending its recent decline. This price rise coincides with a 111% increase in transaction volume on the x402 protocol, driven by AI agent-to-agent comme...
In July 2026, E*TRADE, Fidelity, and SoFi stand out as the best online brokers with $0 commissions on stock and ETF trades and no account minimums, making them ideal for both beginners and experienced investors. E*TRADE excels in customization and of...
